High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis

J Laryngol Otol. 2014 Mar;128(3):236-41. doi: 10.1017/S0022215114000279. Epub 2014 Feb 20.

Abstract

Background: Low-dose clarithromycin has been recommended for the treatment of chronic rhinosinusitis without nasal polyps. However, it is uncertain whether a high dose of clarithromycin is more effective than a low dose.

Methods: Forty-three chronic rhinosinusitis patients were randomised to low-dose or high-dose clarithromycin groups, and clinical efficacy was evaluated. Pre- and post-treatment measures included: nasal symptom assessment, endoscopic inspection (Lund-Kennedy system), a quality of life questionnaire (the Sino-Nasal Outcome Test 20) and examination of cytokine levels (interleukin-5 and -8) in nasal secretions.

Results: The high dose of clarithromycin was significantly better in terms of clinical efficacy than the low dose for the treatment of chronic rhinosinusitis (p < 0.025). Significant differences in nasal cytokine levels (interleukin-5 and -8) were also observed between the low-dose and high-dose groups after short-term clarithromycin treatment (p < 0.025).

Conclusion: Short-term, high-dose clarithromycin appears to be more effective for the treatment of chronic rhinosinusitis than low-dose clarithromycin.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Biomarkers / metabolism
  • Chronic Disease
  • Clarithromycin / administration & dosage*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Interleukin-5 / metabolism
  • Interleukin-8 / metabolism
  • Male
  • Middle Aged
  • Quality of Life
  • Rhinitis / complications
  • Rhinitis / drug therapy*
  • Rhinitis / immunology
  • Sinusitis / complications
  • Sinusitis / drug therapy*
  • Sinusitis / immunology
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Biomarkers
  • Interleukin-5
  • Interleukin-8
  • Clarithromycin